Loading ...
Sorry, an error occurred while loading the content.

13216USA: Vaccine Offers New Control Options for FMD, May 31, 2007, ARS/USDA

Expand Messages
  • Pamela Rice
    Jun 1, 2007
    • 0 Attachment
      Huge development in the world of farming and ranching


      If they had had this vaccine in the UK during its 2001 FMD outbreak,
      that country would not have had to exterminate 6 million healthy
      cattle, sheep, and pigs. The UK did not opt for vaccination back
      then, the more humane alternative, because it would have meant
      letting go of its foot-and-mouth-disease-free status, which would cut
      deeply into its export trade. At that time, an animal having the
      disease or just vaccinated against the disease tested the same. -
      Pamela Rice, author, "101 Reasons Why I'm a Vegetarian"



      <http://www.vivavegie.org/vv101/101reas2007.htm>EXCERPT FROM "101
      REASONS WHY I'M A VEGETARIAN" :
      57 Foot-and-mouth disease is rarely fatal for livestock, but it
      remains a death sentence just the same. When blisters form on hooves
      and lips, and growth slows because of fever, economics prescribe
      execution and incineration. In 2001, Great Britain responded to an
      outbreak by destroying nearly 6 million mostly healthy cattle, sheep,
      and pigs at a cost of [U.S.]$9 billion to save its export trade.
      There were actually only 2,030 known cases of the disease. The rest
      were exterminated to provide buffers to contain the outbreak.



      [EXCERPT FROM FOLLOWING ARTICLE: In addition, the vaccine also makes
      it possible for scientists to determine whether an animal found to
      have FMD antibodies acquired them through vaccination or from
      infection-an important piece of information because of the trade
      restrictions associated with using current vaccines.]


      Vaccine Offers New Control Options for FMD, May 31, 2007, ARS/USDA

      http://www.ars.usda.gov/is/pr/2007/070531.htm

      Vaccine Offers New Control Options for FMD
      By Laura McGinnis
      May 31, 2007

      WASHINGTON, May 31-A new vaccine developed by scientists with the
      U.S. Department of Agriculture's Agricultural Research Service (ARS),
      the Department of Homeland Security (DHS) and a U.S.
      biopharmaceutical company holds promise for protection against
      foot-and-mouth disease which strikes cattle and swine, as well as
      sheep, goats and deer.

      The new vaccine works quickly, demonstrating effectiveness within
      seven days. Tests thus far have shown that vaccinated cattle retain
      immunity for at least 21 days, but scientists expect that future
      studies will show that the new vaccine at least matches the six
      months of immunity provided by current vaccines. The new vaccine has
      been tested on cattle and swine, and is equally effective in both
      species.

      "This signals tremendous promise," said ARS Administrator Edward B.
      Knipling. "Although this is still an experimental vaccine, it has
      made significant developmental progress, and we are optimistic about
      its prospects."

      Although rarely transmissible to humans, foot-and-mouth disease (FMD)
      is devastating to livestock and has critical economic consequences
      with potentially severe losses in the production and marketing of
      meat and milk. Although the United States has not had an FMD outbreak
      since 1929, the disease is still considered a serious threat to the
      nation's economy and food supply.

      Significantly, as this is the first FMD vaccine produced in the
      United States, the federal government can plan adequate supplies for
      the veterinary strategic stockpile. The vaccine is the first
      molecular-based FMD vaccine for cattle, developed by scientists with
      ARS, the Department of Homeland Security's Targeted Advanced
      Development unit (TAD) and GenVec, Inc., a biopharmaceutical company
      based in Gaithersburg, Md. Additional testing is examining the
      vaccine's commercial viability and effectiveness against the various
      serotypes of FMD virus.

      The new vaccine has many benefits. It is administered in a
      nonreplicating adenovirus. It does not require expensive,
      high-containment production facilities, and it can be produced safely
      in the United States because it can be made without using infectious
      FMD materials.

      In addition, the vaccine also makes it possible for scientists to
      determine whether an animal found to have FMD antibodies acquired
      them through vaccination or from infection-an important piece of
      information because of the trade restrictions associated with using
      current vaccines.

      The results of this research effort will be presented on June 2, at
      the 2007 American Society for Gene Therapy meeting in Seattle, Wash.,
      by Douglas E. Brough, senior director of GenVec's Vector Sciences.

      The DHS TAD unit collaborates with ARS and industry to develop
      vaccines and biotherapeutic medication for the U.S. Department of
      Agriculture. ARS is USDA's principal intramural scientific research
      agency.

      [Top

      [Non-text portions of this message have been removed]